140 related articles for article (PubMed ID: 36502356)
21. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
Tap WD; Sharma MG; Vallee M; Smith BD; Sherman ML; Ruiz-Soto R; de Sande MV; Randall RL; Bernthal NM; Gelderblom H
Future Oncol; 2024 Mar; 20(10):593-601. PubMed ID: 37593881
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
[TBL] [Abstract][Full Text] [Related]
23. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
Staals EL; Ferrari S; Donati DM; Palmerini E
Eur J Cancer; 2016 Aug; 63():34-40. PubMed ID: 27267143
[TBL] [Abstract][Full Text] [Related]
24. Malignant Tenosynovial Giant Cell Tumor: The True "Synovial Sarcoma?" A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes.
Al-Ibraheemi A; Ahrens WA; Fritchie K; Dong J; Oliveira AM; Balzer B; Folpe AL
Mod Pathol; 2019 Feb; 32(2):242-251. PubMed ID: 30206409
[TBL] [Abstract][Full Text] [Related]
25. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA; Chawla PA
Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue.
Sugita S; Takenami T; Kido T; Aoyama T; Hosaka M; Segawa K; Sugawara T; Fujita H; Shimizu J; Murahashi Y; Emori M; Hasegawa T
Diagn Pathol; 2022 Nov; 17(1):88. PubMed ID: 36320082
[TBL] [Abstract][Full Text] [Related]
27. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides.
Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB
Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089
[TBL] [Abstract][Full Text] [Related]
28. Optimal Treatment for Tenosynovial Giant Cell Tumor of the Hand.
Kitagawa Y; Takai S
J Nippon Med Sch; 2020 Sep; 87(4):184-190. PubMed ID: 32350187
[TBL] [Abstract][Full Text] [Related]
29. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
Ravi V; Wang WL; Lewis VO
Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109
[TBL] [Abstract][Full Text] [Related]
30. Tenosynovial giant cell tumor of the suboccipital region - A rare, benign neoplasm in this location.
Singh R; Stienen MN; Ganjoo K; Kolahi KS; Cayrol R; Charville GW; Born DE; Zygourakis CC
J Clin Neurosci; 2020 Aug; 78():413-415. PubMed ID: 32631721
[TBL] [Abstract][Full Text] [Related]
31. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
[TBL] [Abstract][Full Text] [Related]
32. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
West RB; Rubin BP; Miller MA; Subramanian S; Kaygusuz G; Montgomery K; Zhu S; Marinelli RJ; De Luca A; Downs-Kelly E; Goldblum JR; Corless CL; Brown PO; Gilks CB; Nielsen TO; Huntsman D; van de Rijn M
Proc Natl Acad Sci U S A; 2006 Jan; 103(3):690-5. PubMed ID: 16407111
[TBL] [Abstract][Full Text] [Related]
33. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.
Bernthal NM; Spierenburg G; Healey JH; Palmerini E; Bauer S; ; Gelderblom H; Staals EL; Lopez-Bastida J; Fronk EM; Ye X; Laeis P; van de Sande MAJ
Orphanet J Rare Dis; 2021 Apr; 16(1):191. PubMed ID: 33926503
[TBL] [Abstract][Full Text] [Related]
34. CSF1 expression in xanthogranulomatous epithelial tumor/keratin-positive giant cell-rich tumor.
Dehner CA; Lo YC; Chopra S; Demicco EG; He K; Hirbe AC; Folpe AL; Chrisinger JSA
Hum Pathol; 2024 Jan; 143():1-4. PubMed ID: 37993023
[TBL] [Abstract][Full Text] [Related]
35. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature.
Giustini N; Bernthal NM; Bukata SV; Singh AS
Clin Sarcoma Res; 2018; 8():14. PubMed ID: 30002809
[TBL] [Abstract][Full Text] [Related]
36. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
[TBL] [Abstract][Full Text] [Related]
37. Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations.
Tsuda Y; Hirata M; Katayama K; Motoi T; Matsubara D; Oda Y; Fujita M; Kobayashi H; Kawano H; Nishida Y; Sakai T; Okuma T; Goto T; Ogura K; Kawai A; Ae K; Anazawa U; Suehara Y; Iwata S; Miyano S; Imoto S; Shibata T; Nakagawa H; Yamaguchi R; Tanaka S; Matsuda K
Int J Cancer; 2019 Dec; 145(12):3276-3284. PubMed ID: 31107544
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; van der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY
Cancer; 2012 Mar; 118(6):1649-55. PubMed ID: 21823110
[TBL] [Abstract][Full Text] [Related]
39. MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment.
Spierenburg G; Suevos Ballesteros C; Stoel BC; Navas Cañete A; Gelderblom H; van de Sande MAJ; van Langevelde K
Insights Imaging; 2023 Feb; 14(1):22. PubMed ID: 36725759
[TBL] [Abstract][Full Text] [Related]
40. Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.
Robert M; Farese H; Miossec P
Front Immunol; 2022; 13():820046. PubMed ID: 35265077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
